Inventor · disambiguated record
Sergio Quezada
Also filed as: QUEZADA SERGIO · QUEZADA SERGIO A
19 granted patents·17 pending applications·188 citations·filing 2006–2024
95Inventor score
Files withTUSK THERAPEUTICS LTD13CANCER RESEARCH TECH LTD8UNIV TEXAS5ACHILLES THERAPEUTICS UK LTD4NOELLE RANDOLPH J3
Top patents by PatentIndex Score
36 records- 0197US10752691B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 25, 2020·12 cites·29 claims
- 0296US10745485B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 18, 2020·11 cites·29 claims
- 0396US10738125B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 11, 2020·11 cites·25 claims
- 0496US8236304B2Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunityNOELLE RANDOLPH J·Filed 2006·Granted Aug 7, 2012·48 cites·4 claims
- 0595US8465740B2Regulatory T cell mediator proteins and uses thereofNOELLE RANDOLPH J·Filed 2011·Granted Jun 18, 2013·29 cites·6 claims
- 0693US8709417B2Combination immunotherapy for the treatment of cancerALLISON JAMES·Filed 2010·Granted Apr 29, 2014·44 cites·6 claims
- 0792US9375475B2Combination immunotherapy for the treatment of cancerUNIV TEXAS·Filed 2014·Granted Jun 28, 2016·18 cites·10 claims
- 0887US10167337B2Combination immunotherapy for the treatment of cancerUNIV TEXAS·Filed 2018·Granted Jan 1, 2019·4 cites·19 claims
- 0987US10023637B2Combination immunotherapy for the treatment of cancerUNIV TEXAS·Filed 2016·Granted Jul 17, 2018·5 cites·19 claims
- 1085US11787866B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2020·Granted Oct 17, 2023·1 cites·11 claims
- 1185US11697688B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Jul 11, 2023·1 cites·26 claims
- 1282US11098121B2“Immune checkpoint intervention” in cancerCANCER RESEARCH TECH LTD·Filed 2016·Granted Aug 24, 2021·4 cites·25 claims
- 1375US11873341B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Jan 16, 2024·0 cites·22 claims
- 1475US11851494B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Dec 26, 2023·0 cites·27 claims
- 1575US2022162315A1Combination Immunotherapy For The Treatment of CancerUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1674US11814434B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Nov 14, 2023·0 cites·26 claims
- 1774US11802161B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Oct 31, 2023·0 cites·26 claims
- 1874US11802160B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2020·Granted Oct 31, 2023·0 cites·10 claims
- 1973US11919960B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Mar 5, 2024·0 cites·28 claims
- 2067US2022323500A1Cancer immunotherapyACHILLES THERAPEUTICS UK LTD·Filed 2022·Application pending·0 cites
- 2165US2024309101A1Anti-cd25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 2264US2019352398A1Combination Immunotherapy For The Treatment of CancerUNIV TEXAS·Filed 2018·Application pending·0 cites
- 2363US2024210396A1Batch release assay for pharmaceutical products relating to t cell therapiesACHILLES THERAPEUTICS UK LTD·Filed 2022·Application pending·0 cites
- 2462US2025239324A1Computational methods for clonal neoantigen identificationACHILLES THERAPEUTICS UK LTD·Filed 2024·Application pending·0 cites
- 2561US2025257141A1Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonistHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2659US2014004537A1Regulatory t cell mediator proteins and uses thereofNOELLE RANDOLPH J·Filed 2013·Application pending·0 cites
- 2759US2019170729A1Regulatory t cell mediator proteins and uses thereofDARTMOUTH COLLEGE·Filed 2018·Application pending·0 cites
- 2858US2023265200A1Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletionCANCER RESEARCH TECH LTD·Filed 2022·Application pending·0 cites
- 2956US2024287456A1A method for producing antigen-specific t cellsACHILLES THERAPEUTICS UK LTD·Filed 2022·Application pending·0 cites
- 3051US2020000903A1Method for Treating CancerCANCER RESEARCH TECH LTD·Filed 2019·Application pending·0 cites
- 3151US2020000904A1Neo-antigen specific t cellsCANCER RESEARCH TECH LTD·Filed 2019·Application pending·0 cites
- 3249US11879014B2Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibodyTUSK THERAPEUTICS LTD·Filed 2018·Granted Jan 23, 2024·0 cites·16 claims
- 3348US2023158073A1Modulation of t cell cytotoxicity and related therapyCANCER RESEARCH TECH LTD·Filed 2021·Application pending·0 cites
- 3445US2019135925A1Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletionCANCER RESEARCH TECH LTD·Filed 2017·Application pending·0 cites
- 3545US2022241333A1Modulation of t cell cytotoxicity and related therapyCANCER RESEARCH TECH LTD·Filed 2020·Application pending·0 cites
- 3642US2018064793A1Method for treating cancerCANCER RESEARCH TECH LTD·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →